Latest updates for Amavex
Fresh curated links around Amavex are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- ADVX Expands Medical Business Consulting Services in Melbourne
- <![CDATA[Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM ]]>
- <![CDATA[Novartis & BoomRay Enter Global License Agreement for Preclinical Radioligand Asset]]>
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
<![CDATA[Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM ]]>
<![CDATA[Novartis & BoomRay Enter Global License Agreement for Preclinical Radioligand Asset]]>
DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
Being marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmaciesTo be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026Program will aim...
Argenx
Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
Averitas
Averitas Anonymous (not verified) Wed, 10/21/2026 - 13:15 field_thread_url https://cafepharma.com/boards/threads/averitas.667825/ board...
NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals
Innovative Delivery Technologies Aimed at Enhancing Bioavailability and Expanding Patient Access Beyond Traditional Injections
BioXcel
BioXcel Anonymous (not verified) Sun, 08/30/2026 - 09:43 field_thread_url https://cafepharma.com/boards/threads/bioxcel.674502/ board na...
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, Oct. 5, 2026 /PRNewswire/ --
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential...
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager
Genentech, Novartis Sue Amneal Over Bid To Sell Xolair Copy
Genentech Inc. and Novartis Pharmaceuticals Corp. have filed a patent infringement suit in Delaware federal court, claiming Kashiv BioSciences' bid to sell a biosimilar copy of the...
NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference
Company highlights ongoing clinical developments in traumatic brain injury (TBI) therapeutics and non-invasive cancer screening, sparking key vendor collaboration discussions.
<![CDATA[Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roc...
<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...
<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...
Revolution Medicines
Revolution Medicines Anonymous (not verified) Wed, 09/30/2026 - 01:04 field_thread_url https://cafepharma.com/boards/threads/revolution-medicines.709803/...
<![CDATA[Osivax And GC Biopharma Enter Collaboration to Develop Next Generation Influenza Vaccine ]]>
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Mayne Settles US Patent Suit With Teva Over Generic Imvexxy
ASX-listed Mayne Pharma announced on Friday another settlement related to its oestradiol vaginal insert Imvexxy, with medicines maker Teva Pharmaceuticals USA Inc. agreeing not to...
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.5 millionEXXUA n...
<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...
Axogen
Axogen Anonymous (not verified) Mon, 09/14/2026 - 18:53 field_thread_url https://cafepharma.com/boards/threads/axogen.530270/ board name...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.